ArticleJournal of medical case reports2025
Clinical characteristics and gene mutation analysis of a family with hereditary spastic paraplegia type 11: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAutosomal recessive hereditary spastic paraplegia with thinning of the corpus callosum is a complex hereditary spastic paraplegia. Spastic paraplegia type 11 (SPG11) mutation is the most frequent form of autosomal recessive hereditary spastic paraplegia with thinning of the corpus callosum. The study of SPG11 in China is small scale, and only a few gene mutations have been reported. CASE PRESENTATION: We report the case of a family with autosomal recessive hereditary spastic paraplegia with thinning of the corpus callosum. We describe a 20-year-old Han female patient with spastic gait and cognitive impairment 2 years ago, whose brain imaging revealed a thinning corpus callosum. Her 14-year-old Han brother had only a spasmodic gait. Detailed history, physical examination, and supplementary examination were performed to rule out the cause of spastic paraplegia. To identify pathogenic mutations, we used target sequence capture sequencing technology to detect hereditary-spastic-paraplegia-related genes in family members in combination with Sanger sequencing. We found two new complex heterozygous mutations in SPG11: c.6738_6739insT and c.5934_5935insTAACCTGGAA. The Glu2247 amino acid codon was changed to a stop codon (p.Glu2247Ter), and the Val1979 amino acid was also changed to a stop codon (p. Val1979Ter). Bioinformatics analysis predicted that these mutations would result in a loss of protein function. In silico analysis of the mutant sequences was performed.
conclusionWe found two novel complex heterozygous mutations, c.6738_6739insT and c.5934_5935insTAACCTGGAA, which enriched the phenotypic spectrum of SPG11 mutations related to hereditary spastic paraplegia and may help to determine the molecular mechanism of hereditary spastic paraplegia with thinning of the corpus callosum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.